Trevena, Inc. Stock price
Is Trevena, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Trevena, Inc. Stock Analysis
Analyst Opinions
6 Analysts have issued a Trevena, Inc. forecast:
Analyst Opinions
6 Analysts have issued a Trevena, Inc. forecast:
Don't miss a Thing! We will send you all news about Trevena, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
| Head office | United States |
| CEO | Ms. Bourdow |
| Employees | 23 |
| Founded | 2007 |
| Website | www.trevena.com |


